We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Realm Thera. | LSE:RLM | London | Ordinary Share | GB00B3XBCR18 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 11.50 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 10.00 | 13.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 11.50 | GBX |
Realm Thera. (RLM) Share Charts1 Year Realm Thera. Chart |
|
1 Month Realm Thera. Chart |
Intraday Realm Thera. Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 11/2/2021 | 17:26 | FANTASTIC MANAGEMENT. PHASE 11 TRIALS | 63 |
| 27/2/2019 | 12:23 | Realm with charts | 4 |
| 14/8/2018 | 13:37 | Realm Therapeutics (RLM) One to Watch | - |
| 18/10/2017 | 14:21 | Realm Energy | 22 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 07/10/2019 09:52 by cjohn I wonder if any past holders of RLM now hold Essa Pharma shares?I read through various ESSA (EPIX) documents - research pathways etc - and also got myself as informed as I could about therapeutic approaches to prostate cancer. And decided to hold on to the ESSA shares. As far as I can tell, there's a really promising pipeline of molecules, apart from the current lead drug. Currently, up 100% on my implied ESSA buy price; and the share price doesn't look exorbitant given the potential upside. |
Posted at 08/4/2019 12:49 by eezymunny A fair chance it'll tank today I guess...uk.advfn.com/stock-m |
Posted at 04/3/2019 16:22 by eezymunny HL say..."What is happening? The Board of Realm Therapeutics plc has announced proposals to cancel the Company’s Ordinary Shares from trading on AIM (The Alternative Investment Market). It is expected that the Company’s Shares will be delisted with effect from the close of business on 26 March 2019. However, the Company is offering the option of converting the Ordinary Shares into American Depositary Shares (ADSs) prior to the Delisting, thereby continuing to offer a trading platform for your holding. One ADS represents 25 Ordinary Shares and will trade on the NASDAQ Stock Market in the US. What is an ADS? ADSs are a form of stock traded in the US that represent a number of Shares in a foreign Company. The ADSs are created by a Depositary, in this instance Citibank NA. Do I need to take any action? For the Delisting to become effective, it must be approved at a General Meeting to be held on 15 March 2019. If you would like to submit a vote for or against the resolution to delist the Shares, please provide us with your voting instruction by noon Tuesday 12 March 2019 by clicking on your Stocks & Shares ISA in the ‘My Accounts’ section of our website. Please then select the dark blue Corporate Actions Icon alongside your Realm Therapeutics plc Shares and follow the online instructions provided. Alternatively you can give an instruction over the telephone on 0117 900 9000, subject to confirmation of your security details. You also have 3 options to consider for your holding in Realm Therapeutics, should the Delisting be approved: Option 1 – DEFAULT – Do nothing and receive ADSs. If you continue to hold your Shares at close of business on 15 March 2019 and the delisting is approved we will automatically arrange for them to be converted into ADSs, unless you notify us otherwise. This is to ensure you can still trade your investment and do not have to pay the 1.5% stamp duty and a US$0.05 per ADS conversion fee that would be levied on any conversion instructions we process after this date. You will receive 1 ADS in place of every 25 Shares held, with any fractional entitlement to ADSs being paid to you as cash. Option 2 – Request to maintain your Ordinary Shares and not convert to ADSs. If you do not sell your holding before 15 March 2019, but do not wish for us to automatically convert them into ADSs, you must inform us of this before 4.30pm on Friday 15 March 2019. Please note that if the delisting proceeds there will be no market in which you can trade Shares and you would therefore find it extremely difficult to realise the value of your holding. Following the delisting any future conversion of Shares into ADSs would be a lengthy process and incur 1.5% stamp duty and a US$0.05 per ADS conversion fee. To give an instruction to not convert your Shares please call us on 0117 980 9912. Option 3 – Sell your holding. If you wish to sell your holding before the proposed listing cancellation you must do so before close of business on 15 March 2019, unless you have requested us not to convert your Shares into ADSs (Option 2 above) in which case you will still have the opportunity to trade up to 26 March 2019. The trade will be placed in accordance with our terms and conditions and subject to the standard Stockbrokers commission rates. To sell these Shares please phone us on 0117 980 9800 or you can place a trade online. Please note that if the cash consideration of a sale does not exceed the commission payable then the sale will not be executed. Please note that although Hargreaves Lansdown will endeavor to sell your Shares it may not be possible to sell all, or even any, of your Shares if a market for the Shares no longer exists. If you dispose of your holding before shareholder approval for the Delisting has been granted you do so at your own risk. Please read the appendix of this message in order to obtain further information regarding the Delisting and Conversion to ADSs to help make your decision. Important information for holders of Realm Therapeutics Shares within a Stocks & Shares ISA Please note under HMRC rules unlisted Shares are not eligible to be held within a Stocks & Shares ISA. As a result, if the delisting becomes effective, any holding of Realm Therapeutics plc Shares within a Stocks & Shares ISA will need to be removed within 30 days of the effective date of the delisting (by 26 April 2019). Additionally, as the underlying Ordinary Shares will not be listed the ADSs will also be a ineligible to be held within a Stocks & Shares ISA and as such would need to be removed from your ISA by 26 April 2019. Other information and warnings Should you have any queries relating to the delisting please contact us on 0117 900 9000. Please note, we can provide factual assistance but cannot provide advice about which option you should choose. We hope you are satisfied with our service. If you would like to set up new products, or transfer other assets you hold to Hargreaves Lansdown please go to www.hl.co.uk or call our Investment Helpdesk on 0117 900 9000. Yours sincerely Charlie Balmer Charlie Balmer Corporate Actions APPENDIX QUESTIONS AND ANSWERS Why is this happening? “The Directors have undertaken a review of the advantages and disadvantages associated with the continued admission of the Ordinary Shares to trading on AIM, considering both access to the relevant equity capital markets and having a second public market in the Company's securities versus the cost and management time associated with maintaining a dual-quotation on AIM. Costs of the AIM listing include fees payable to the London Stock Exchange, nominated adviser and brokerage fees, shareholder communication time and costs, professional advisory fees and expenses. “The Company also notes the costs, professional advisory fees and expenses associated with the compliance with the Takeover Code in the context of the Formal Sale Process, and reiterates the confirmation of the Takeover Panel that, subject to the AIM Delisting becoming effective, the Takeover Code will no longer apply to the Company on the basis that the Company's place of central management and control is outside of the UK, Channel Islands and the Isle of Man. “The Board notes that approximately 40% of Ordinary Shares are, as at the date of this document, held in the form of ADSs. The Board believes the Company does not merit the ongoing costs and regulatory complexities associated with a dual listing and that it would be advantageous for all Shareholders to seek, to the extent possible, to combine trading volumes of the Ordinary Shares on AIM and the ADSs on the Nasdaq Capital Market onto a single trading exchange (Nasdaq Capital Market, wherein trades will be made in the form of ADSs). (Source: Shareholder Notice - February 2019) When will I receive the ADSs? If your holding is converted into ADSs at this opportunity they will be credited to your portfolio on receipt, expected to be around 28 March 2019. Will I be able to trade the new ADSs? Realm Therapeutics ADSs are listed and traded on NASDAQ under the ticker ‘RLM’. Once exchanged from Ordinary Shares, they will be tradeable over the telephone or by post only. Please note that trades will be placed in US Dollars and converted to Sterling on receipt by Hargeaves Lansdown, subject to the prevailing exchange rate at that time and our standard currency conversion fees. Furthermore, if you choose to convert to ADSs please note that you will not have any voting rights. Additional charges may be applied by the Depositary to ADS holders for Dividends and Corporate Actions, in some instances these charges may be passed on to you from Hargreaves Lansdown. You can find more information on our overseas Share dealing service at |
Posted at 27/2/2019 23:19 by eezymunny Slowly rising towards cash/share value (17-20p post sale?).Mr Market has perhaps been rather thick and slow here.... |
Posted at 15/2/2019 22:25 by the stinger Cash takeover is around £22m ,, 17p a share?... now priced at 7p?.... |
Posted at 26/12/2018 23:56 by arthur_lame_stocks I bought some more of these at 6p just before Christmas. At that price the discount to cash is significant with the chance of value realisation in the short term.It seems like a really attractive risk reward situation to me. |
Posted at 15/8/2018 09:32 by edmonda AIM:RLM - "Review underway after Atopic Dermatitis miss"RLM’s randomised, double-blind, placebo controlled, Phase II clinical trial, PR022 showed no difference from vehicle in the primary endpoint of percentage change in Eczema Area Severity Index (EASI) versus baseline. The Company is now analysing the data to interpret the top-line result, as well as the other data collected in the study. The conclusions of this review will be used to inform decision-making going forward, and this includes evaluating the implications of these data for RLM’s preclinical HOCl dermatology pipeline in Acne and Psoriasis – both of which had been making good progress. RLM indicates that it will also review the possibility of acquiring one or more new assets, although no specific detail is available. They expect to disclose the outcome of the review in September. Pending the outcome of the review, we are suspending our forecasts and valuation that we can update when the Group’s strategic direction becomes clearer in September. In the meantime, RLM has the benefit of significant cash on the balance sheet, an experienced Executive team, and substantial IP filed. Read the full note here ... |
Posted at 14/8/2018 23:32 by cerrito Looking at what support their cash pile can give the share price They have 116 m shares and at the end of June US23m. Cash burn in H1 was US10m, including the NASDAQ listing costs. I am assuming they have reduced R&D on acne/ psioriasis to the minimum until next month when they make their review. At the end of Sept cash/ cash equivalents I estimate will be Us20m approx or approx 13.5p per share. Of course in the extremely unlikely event that they were to liquidate the company this cash balance would go down to say 11p a share after the costs of liquidation offset by the sale of their IP. PS Went on to the Nasdaq webpage to see what RLM did there but said price unchanged at $0 and no trades so perhaps RLM not live on NASDAQ yet. |
Posted at 14/8/2018 13:37 by danieldanj Realm Therapeutics (RLM) News Out Just Now |
Posted at 14/8/2018 11:21 by cerrito I also substantially reduced my exposure this morning and indeed am surprised that the price had not fallen further.Am planning to listen to the conference call. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
